Angelina Suleymanova

Angelina Suleymanova

Auto-generated profile, based on publicly available information

Angelina Suleymanova

The Russian National Research Medical University named after N.I. Pirogov, Moscow, Russia, Moscow, Russian Federation

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 February 2023 in PULMONOLOGIYA
Verified
Journal Article
Open access
PDF file
ACAlexander Chuchalin
Alexander Chuchalin
PYP. K. Yablonskiy
P. K. Yablonskiy
TRT. V. Rubanik
T. V. Rubanik
OCO. A. Chernyavskaya
O. A. Chernyavskaya
VNV. V. Naumov
V. V. Naumov
ASA. K. Suleymanova
A. K. Suleymanova
Post-COVID syndrome develops after COVID-19 (COronaVIrus Disease 2019) and leads to cumulative effects in the form of shortness of breath and impaired lung function. Notably, patients with airway inflammation and COVID-19 were found to have increased concentrations of hyaluronic acid (HA). Since bovhyaluronidase azoximer (Longidase®) catalyzes the hydrolysis of HA, this drug has the potential to reduce HA levels and improve lung function in patients with post-COVID syndrome.The aim of the DISSOLVE trial, which was conducted early in the pandemic, was to investigate the efficacy and safety of bovhyaluronidase azoximer in patients with symptoms associated with post-COVID syndrome.Methods. An open, prospective, controlled, comparative, multicenter clinical trial (NCT04645368) included adult patients (n = 160) who had post-COVID syndrome. Patients in the treatment group (n = 81) received bovhyaluronidase azoximer, and individuals in the control group (n = 79) were followed up without intervention. The study included physical examination, evaluation of forced vital capacity (FVC), assessment of dyspnea with the Modified Medical Research Council Dyspnea Scale (mMRC), 6-minute walking test, and pulse oximetry. These indicators were measured on 3 visits, at days 1 (baseline), 75, and 180. In addition, the number of patients who experienced adverse events and serious adverse events were recorded.Results. Baseline patient characteristics in the treatment group and the control group were similar. In the treatment group, there was a statistically significant reduction in residual pulmonary abnormalities after visit 2 (day 75) and visit 3 (day 180). In addition, FVC, pulse oximetry values, and functional exercise tolerance increased statistically significantly at days 75 and 180 compared to baseline. The mMRC scores for dyspnea decreased statistically significantly in the treatment group over 75 days. The safety profile of the drug was reported to be favorable throughout the study. Conclusion. Treatment with bovhyaluronidase azoximer in patients with post-COVID syndrome showed improvement in FVC, pulse oximetry, functional exercise tolerance, and mMRC dyspnea.

10 June 2021 in PULMONOLOGIYA
Verified
Journal Article
Closed access
PDF file
IBIrina Baranova
Irina Baranova
ASA. K. Suleymanova
A. K. Suleymanova
VZV. V. Zakharova
V. V. Zakharova
The aim of the study was to evaluate various methods of osteoporosis diagnostics (FRAX® and Dual-energy Х-Ray absorptiometry – DXA) and the sequence of their application in the diagnostic algorithm in COPD patients without a history of large bone fractures. Methods. Cross-sectional study of 115 COPD patients without exacerbation (93 men and 22 women, mean age 67.2 ± 7.1 years). The study included clinical examination, FRAX® estimation and comparison of the 10-year probability of a major osteoporotic fracture (MOF) with the Russian intervention threshold, spirometry, DXA of lumbar spine and proximal femur, semi-quantitative radiographic morphometry by Genant. All patients were examined using several methods that are possible in clinical practice: 1) FRAX® without DXA; 2) FRAX® + DXA in patients with intermediate 10-year probability of MOF and recalculation of FRAX® probability including femoral neck bone mineral density (BMD); 3) FRAX® + DXA in patients with intermediate 10-year probability of MOF. Take into account DXA results; 4) DXA without FRAX® ; 5) DXA + recalculation of FRAX ® for individuals with normal BMD or osteopenia. Results. In the whole sample of patients 1 – 5 diagnostic methods revealed 5.1, 7.0, 15.7, 44.3, 45.2% of individuals with osteoporosis, respectively. In men, the methods using FRAX ® (1 – 3) gave unsatisfactory results – the number of patients requiring treatment did not exceed 4.3%, while DXA revealed osteoporosis in 43%. FRAX® + DXA analysis in patients with intermediate 10-year probability of MOF (3 th method) was the best for women. The main independent predictors of low bone mineral density were post-bronchodilator FEV 1 ≤ 30% predicted and/or long-term oral glucocorticoid use. Asymptomatic vertebral fractures were detected in 11 patients. Before the radiographic morphometry, treatment would have been prescribed only 1 patient for the 1th or 2th methods; 5 patients – 3th method and 9 patients using 4th or 5th methods. Conclusion. The use of the Russian FRAX® model in men with COPD revealed a very low percentage of people who need osteoporosis treatment; DXA was the optimal diagnostic method. If it`s not possible to perform DXA in the most COPD patients, it should be prescribed to people with very severe bronchial obstruction and/or taking long-term oral glucocorticoid therapy. Regardless of the BMD parameters, semi-quantitative X-ray morphometry should be performed to diagnose asymptomatic vertebral fractures.

28 June 2023 in Rheumatology Science and Practice
Verified
Journal Article
Open access
PDF file
EGE. N. Gladkova
E. N. Gladkova
ONO. A. Nikitinskaya
O. A. Nikitinskaya
ISI. A. Skripnikova
I. A. Skripnikova
MMM. A. Myagkova
M. A. Myagkova
IBIrina Baranova
Irina Baranova
ЮПЮ. В. Полякова
Ю. В. Полякова
According to the European guidelines for osteoporosis, the same FRAX intervention threshold is suggested for men as for women. At the same time, in the Russian Federation, according to research data, an extremely low proportion of identified men who are subject to the initiation of osteoporosis therapy. The female intervention threshold identifies only 1.1 to 4% of men for treatment. Aim – to develop and evaluate various options for the intervention threshold using the FRAX calculator for men in the Russian Federation and adopt the most acceptable intervention threshold by consensus. Material and methods. Delphi voting was conducted among 18 Russian experts who have publications and personal reports about their experience with the FRAX calculator. For discussion, 5 intervention threshold options with the corresponding rationale based on the literature reference were presented, as well as the proportion of men of different ages to be initiated in each of the options (based on several Russian population-based studies). Anonymous voting was carried out using the Delphi method with questionnaire placed in the Google form. It was proposed to evaluate all options for intervention thresholds on a 9-point Likert scale. Consensus was considered reached if the intervention threshold reached a Likert score of 7 or more points in 80% or more of the experts. The rating of each intervention threshold option was expressed as mean and standard deviations. Results. In the first round of voting, the maximum rating and percentage of agreement is reached for the 9% fixed interference threshold option based on the FRAX calculation. The rating was 7.72±1.6 points, the percentage of experts’ agreement was 88.9%. A fixed threshold of 9% determined 13–19.5% of men aged 50 years and older to be treated for osteoporosis, while their proportion increased to 26–38% at the age of 85 years and older. Conclusion. The consensus of experts of the Russian association on osteoporosis suggests initiating treatment of osteoporosis in Russian men with a 10-year probability of major osteoporotic fractures according to FRAX of 9% or higher.

27 March 2020 in Terapevticheskii arkhiv
Verified
Journal Article
Open access
PDF file
ASA. K. Suleymanova
A. K. Suleymanova
IBI. A. Baranova
I. A. Baranova
СКСулейманова Ангелина Курбановна
Сулейманова Ангелина Курбановна
Chronic obstructive pulmonary disease (COPD) is a group of diseases with high levels of comorbidity. Pathological changes of peripheral skeletal and respiratory muscles in COPD patients, which are often underestimated, occupy a special place. Aim. To study the relationship between functional and quantitative parameters of the peripheral (limb muscle) and respiratory muscles in COPD patients. Materials and methods. 127 patients (98 men/29 women, mean age 67.68.2 years) were under observation without acute COPD. All COPD patients were classified according to GOLD (2019) into groups A, B, C, D. The algorithm of the European Working Group on Sarcopenia in Older People (EWGSOP2) was used to diagnose sarcopenia. The muscle mass was measured using dual energy X-ray absorptiometry (DXA) and the appendicular lean mass index (ASM) was estimated. Maximal inspiratory pressure (MIP) and maximal expiratory pressure (MEP) were measured by body plethysmograph MasterScreen Body. Quantitative assessment of thoracic muscle cross-sectional areas were performed using the CT scan using Vidar Dicom Viewer software. Results. Sarcopenia was diagnosed in 43.3% of COPD patients. Respiratory muscle dysfunction was determined in 66.1% of patients with COPD, its probability increased in groups C and D in comparison with groups A and B [chance ratio 6.6 (95% confidence interval 2.915.0); p0.0001]. Correlations between the functional parameters of sarcopenia and respiratory muscle strength as well as between the mass of peripheral skeletal muscles and respiratory muscle area have been established according to the data of computerized tomography (р0.01). Sarcopenia as well as respiratory muscle dysfunction was observed more frequently in persons with severe and extremely severe airway obstruction and in patients with predominantly emphysematic COPD phenotype (p0.01). Conclusion. Sarcopenia is a frequent comorbidity in COPD and its development is connected with the severity of the course of the main disease. Correlation between parameters of peripheral (limb muscle) and respiratory muscles in patients with COPD has been determined.

28 September 2019 in European Respiratory Journal
Verified
Conference Paper
Closed access
ASAngelina Suleymanova
Angelina Suleymanova
IBIrina Baranova
Irina Baranova
OBOlga Brodskaya
Olga Brodskaya
ABAlexandra Ball
Alexandra Ball
ESElizaveta Sidenko
Elizaveta Sidenko
RSRodion Skvorcov
Rodion Skvorcov
Introduction: Sarcopenia (progressive and generalised loss of skeletal muscle mass and function) is a common comorbidity in COPD patients. Consequences of sarcopenia on individual quality of life are poorly understood. Aim: To compare the quality of life in persons with primary sarcopenia with that of COPD patients of the same age (with secondary±primary sarcopenia). Methods: In the cross-sectional study, 76 persons were included. They were divided into 4 groups: 1) persons ≥65 years without sarcopenia (n=19); 2) persons ≥65 years with sarcopenia (n=14); 3) COPD patients without sarcopenia (n=20); 4) COPD patients with sarcopenia (n=25). Sarcopenia was diagnosed according to EWGSOP2 algorithm. All respondents completed the SarQoL (Sarcopenia and Quality of Life) questionnaire. We analyzed the total SarQoL score and the individual domain scores (Physical and Mental Health, Locomotion, Body Composition, Functionality, Activities of daily living, Leisure activities, Fears). Results: Patients of all groups were comparable in age, sex, comorbidity index. Sarcopenic subjects had a lower quality of life compared to non-sarcopenic participants (p<0.05). COPD patients without sarcopenia presented a quality of life score of 64.1±13.6 compared to a score of 85.4±6.5 for their peers; the differences were found in all individual domains scores (p<0.05). When analyzing sarcopenia groups, the total SarQoL score was lower in COPD patients than in subjects of the same age (50.4±15.7 vs 60.9±12.3, p<0.05). We also identified a significant score decrease across three domains (Locomotion, Activities of daily living and Fears). Conclusion: COPD patients with sarcopenia have a lower quality of life than subjects with primary sarcopenia of the same age.

7 September 2020 in European Respiratory Journal
Verified
Conference Paper
Closed access
ASAngelina Suleymanova
Angelina Suleymanova
IBIrina Baranova
Irina Baranova
Introduction: The effects of vitamin D are not limited to the maintenance of calcium and bone homeostasis. Vitamin D deficiency is also known to contribute to the risk of many inflammatory diseases. Aim: to analyze the relationship between serum vitamin D level and the main characteristics of COPD patients. Materials and Methods: This cross-sectional study included 75 patients with stable COPD (63 males/12 females, mean age 67,4 ± 8,7 years). The respiratory muscle strength (maximal inspiratory pressure (MIP) and maximal expiratory pressure (MEP)) were measured by body plethysmograph MasterScreen Body. The level of 25 (OH) D was assessed by chemiluminescent immunoassay on microparticles according to international standards. Results: Low levels of serum vitamin D (median 13,2 (12;18,7) ng/ml) were found in 72 COPD patients (96%): insufficient vitamin D level(≥20≤30 ng/ml) was defined in 10 patients (13,3%), vitamin D deficiency (≥10-20 ng/ml) – in 68 patients (51%) and pronounced vitamin D deficiency (˂10 ng/ml) - in 11 patients (14,7%). Although vitamin D deficiency was found in all COPD patient9s groups, the lowest levels were observed in the group D (p˂0,05). Serum vitamin D levels correlated significantly with smoking index (r=-0,34), disease duration (r=-0,42), MIP (r=0,48) and MEP (r=0,40), FEV1 (r=0,32). Patients with pronounced vitamin D deficiency have respiratory muscle dysfunction more often than patients with higher serum 25(OH)D concentration (OR = 1,6 (95% CI 1,3-1,9, p=0,01). Conclusions: Vitamin D deficiency is often observed in COPD patients and it associated with the severe airflow limitation, severity and duration of the disease, respiratory muscle strength, and smoking index.